Ex Parte LEE - Page 19


                 Appeal No.  2004-1346                                                       Page 19                  
                 Application No.  08/971,338                                                                          
                 degree of specificity that GDF-1 will share the activity of a particular TGF-β                       
                 isoform, or any other particular member of the TGF-β superfamily to which GDF-                       
                 1 is least homologous with.                                                                          
                        Accordingly, we also disagree with appellant’s assertion (Brief, page 9)                      
                 that “the [e]xaminer provides no evidence that those of skill in the art at the time                 
                 the invention was made would have believed that members of the TGF-β super                           
                 family exhibit such diverse activities as to preclude prediction of function based                   
                 on this family assignment.”  In our opinion, as discussed above, the evidence                        
                 relied upon by appellant – Akhurst – speaks for itself.                                              
                        Thus, while appellant asserts (Brief, page 9), the specification “predicted                   
                 that the GDF-1 protein was likely to play an important role in mediating                             
                 developmental decisions related to cell differentiation…,” appellant’s                               
                 specification fails to identify what precise role GDF-1 plays.  In this regard, we                   
                 agree with the examiner (Answer, page 14), “the specification is an invitation to                    
                 experiment without clear direction or guidance as to the particular biological                       
                 activity to investigate.”                                                                            


                 III.  Post-filing date evidence:                                                                     
                        Appellant asserts (Brief, page 10), “[t]he Rankin reference was submitted                     
                 to demonstrate that the GDF-1 protein has the utilities that were predicted in the                   
                 specification, and is suitable evidence for that purpose even though it was                          
                 published after the filing date of the present application.”  In this regard,                        
                 appellant asserts (id.), Rankin’s “results with the GDF-1 knockout mouse prove                       







Page:  Previous  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  Next 

Last modified: November 3, 2007